Partnering

Lupagen works with biopharma companies combining their transgene product or novel targets with our Side CAR-T® delivery system to develop first-in-class extracorporeal cell & gene therapies. Our proprietary delivery technology, including devices, kits and nanoparticle formulations, is available via contract development and supply agreements on a non-exclusive basis.

Lupagen's technology can simplify, enable, and improve a wide range of cell & gene therapies involving peripheral blood cells including lymphocytes, monocytes and hematopoietic stem cells including, but not limited to the following therapy types:

CAR/TCR-based cell therapies (T-Cell,

NK Cell, Macrophage)

Gene Therapy

(Gene Editing)

Targeted Drug Delivery (Immunosuppression, Autoantigens)

Other non-viral

Please feel free to contact us for more information if you are a biopharma company or academic institution looking for effective alternatives to ex vivo and in vivo cell & gene therapy delivery and need to:

Mitigate biodistribution and immunogenicity challenges
Enable redosing
Lower manufacturing costs and complexity
Broaden treatable patient population and access
Avoid chemotherapy preconditioning regiments
Shorten vein-to-vein treatment time
Accelerate pathway to the clinic